Stryker Exceeded Analysts’ Sales Estimates in 2Q17 – Market Realist

What We Should Know about Stryker's 2Q17 Earnings PART 1 OF 3

On July 27, 2017, Stryker (SYK) released its 2Q17 earnings. The company reported strong earnings and exceeded analysts expectations. However, on the day of the release, Stryker stock fell approximately 1.3% from the closing price of $145.70 on July 26, 2017. Notably, Stryker also raised its 2017 guidance during the 2Q17 earnings announcement.

Interested in SYK? Don't miss the next report.

Sign Up

Receive e-mail alerts for new research on SYK

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

In 2Q17, Stryker earned revenue of ~$3.0 billion. It registered strong growth of ~6.1% on a YoY (year-over-year) basis and exceeded analysts estimates of $2.98 billion in revenues.

The currency-neutral sales growth for the quarter came in at 6.9% on a YoY basis. The growth included a 0.20% acquisitions contribution and a negative pricing impact of around 1.5%. The companys organic revenue growth was thus around 6.7%. Strykers sales growth was driven by strong results across all three of its business segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The company continued to witness strong results in Canada and Europe led by its Transatlantic Operating Model (or TOM). For brief details on TOM, read How Stryker Plans to Capture the International Markets.

Organic sales growth of 6.7% for Strykers MedSurg segment was driven by strong instrument sales in the United States. Its Orthopaedics segment witnessed strong sales growth of 6.2%. Orthopaedics sales were driven by strong knee sales as well as strong trauma and extremities sales, led by the strong demand for Strykers 3D-printed products, including its Triathlon Knee and foot and ankle portfolio. Neurotechnology and Spine sales registered an organic growth of around 7.9%, which was mainly led by strong momentum across the companys neurotechnology portfolio. Spine sales continued to be impacted by supply issues in the United States

Sales in the United States rose approximately 7.2%, and international sales rose approximately5.5%. International sales witnessed strong contributions from Europe and Australia, while emerging markets continued to recover.

Strykers peers Zimmer Biomet Holdings (ZBH), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) earned revenues of about $1.9 billion, $5.0 billion, and $6.6 billion, respectively, for their recently ended quarters. For exposure to Strykers growth potential, you can invest in theiShares Core S&P 500 (IVV), which holds approximately 0.21% of its total holdings in SYK.

Read more from the original source:

Stryker Exceeded Analysts' Sales Estimates in 2Q17 - Market Realist